

β -arrestin2 regulates TRAIL-induced HepG2 cell apoptosis via the Src-extracellular signal-regulated signaling pathway

ZHILIN QI¹, SHIMEI QI¹, LIN GUI² and LEI SHEN³

Departments of ¹Biochemistry, and ²Microbiology and Immunology, Wannan Medical College, Wuhu, Anhui 241002; ³Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, Nanjing, Jiangsu 210023, P.R. China

Received May 8, 2015; Accepted February 8, 2016

DOI: 10.3892/mmr.2016.5216

Abstract. β -arrestins, including β -arrestin1 and β -arrestin2, two ubiquitously expressed members of the arrestin family in various types of tissue, are adaptor proteins that modulate the desensitization and trafficking of seven membrane-spanning receptors. Recently, β -arrestins have been shown to bind to numerous signaling molecules, including c-Src and mitogen-activated protein kinase family members. In addition, accumulating evidence has suggested that β -arrestins are involved in the anti-apoptosis signaling pathway by associating with kinases, such as Akt and ERK, and altering their activities. However, the role of β -arrestins in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis remains unclear. In the present study, β -arrestin2, but not β -arrestin1, was observed to modulate TRAIL-triggered HepG2 cell apoptosis by regulating activation of the Src-extracellular signal-regulated kinase (ERK) signaling pathway. Using overexpression and RNA interference experiments, β -arrestin2 was demonstrated to prevent TRAIL-induced HepG2 cell apoptosis. Additionally, β -arrestin2 exerted an additive effect on TRAIL-induced activation of Src and ERK. Furthermore, downregulating β -arrestin2 expression attenuated the TRAIL-induced activation of Src and ERK survival signaling and enhanced TRAIL-induced apoptosis. PP2, a pharmacological inhibitor of Src, reduced activation of the Src-ERK signaling pathway and enhanced TRAIL-induced

HepG2 cell apoptosis. Co-immunoprecipitation experiments demonstrated a physical association between β -arrestin2 and Src, and TRAIL stimulation resulted in enhanced quantities of the β -arrestin2/Src complex. A notable interaction was identified between β -arrestin2 and death receptors (DR)4 and 5, but only in the presence of TRAIL stimulation. To the best of our knowledge, these findings are the first to demonstrate that β -arrestin2 mediates TRAIL-induced apoptosis by combining with DRs and Src, and regulates the activation of Src-ERK signaling in HepG2 cells. It is hypothesized that the formation of a signaling complex comprising DR, β -arrestin2 and Src is required for the action of TRAIL on HepG2 cell apoptosis, which provides a novel insight into analyzing the effects of β -arrestin2 on protecting cells from TRAIL-induced apoptosis.

Introduction

β -arrestins, including β -arrestin1 and β -arrestin2, two ubiquitously expressed members of the arrestin family in various types of tissues, localize in the cytoplasm and plasma membrane, and modulate the desensitization and trafficking of seven transmembrane receptors (1,2). Recent evidence revealed that β -arrestins also served as multi-functional adaptors that contribute to regulating multiple signaling molecules. For example, β -arrestins associate with c-Src and mitogen-activated protein kinase (MAPK) family members, including extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (3,4). The binding of β -arrestins with these signaling molecules modulates phosphorylation, ubiquitination and/or subcellular distribution of their binding partners (5,6). The biological and clinical behaviors of numerous types of tumor are largely determined by multiple molecular signaling pathways. In addition, it was recently established that β -arrestins were involved in signaling events responsible for tumor viability and metastasis (7). It has also been reported that β -arrestins are involved in the anti-apoptosis pathway by associating with kinases such as Akt and ERK and altering their activities (4,8,9). However, the role of β -arrestins in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis remains unclear.

TRAIL induces apoptosis in a variety of cancer cell lines by interacting with their death receptors (DRs) while causing minimal or no toxicity to normal cells, establishing it as an attractive agent for cancer therapy (10). However, numerous

Correspondence to: Dr Zhilin Qi or Dr Shimei Qi, Department of Biochemistry, Wannan Medical College, 22 Wenchang West Road, Wuhu, Anhui 241002, P.R. China
E-mail: 422627721@qq.com
E-mail: 358116620@qq.com

Abbreviations: DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; DR, death receptor; RNAi, RNA interference; DAPI, 4',6-diamidino-2-phenylindole; GFP-ARRB2, green fluorescent protein-tagged β -arrestin2

Key words: β -arrestin2, Src, extracellular signal-regulated kinase, tumor necrosis factor-related apoptosis-inducing ligand, apoptosis

types of cancer cell have been shown to be resistant to TRAIL-induced apoptosis, including hepatic carcinoma and human breast cancer cells (11,12). TRAIL signaling involves the activation of effector caspases and initiation of apoptosis, and thus the activation of pro-survival signaling pathways involving nuclear factor- κ B, Akt and MAPKs may have contributed to the development of TRAIL resistance in tumor cells (13,14).

In the present study, the role and molecular mechanisms underlying the modulation of TRAIL-mediated apoptosis by β -arrestin2 in HepG2 cells was investigated.

Materials and methods

Antibodies and reagents. Monoclonal rabbit antibodies against poly ADP ribose polymerase (PARP; 9532s; 1:1,000), pro-caspase-3 (9665s; 1:1,000), cleaved caspase-3 (9664s; 1:500), Src (2109s; 1:1,000), phosphorylated (p)-Src (Tyr416; 6943s; 1:1,000), ERK (9102s; 1:1,000), p-ERK (Thr202/Tyr204; 4376s; 1:1,000), DR5 (8074s; 1:1,000), β -arrestin2 (3857s; 1:1,000) and β -actin (4970s; 1:1,000) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). In addition, mouse monoclonal antibody against DR4 (sc-8411; 1:500) and monoclonal rabbit antibody against β -arrestin1 (sc-53780; 1:500) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Polyclonal rabbit anti-GAPDH antibody (AP0063; 1:1,000) was purchased from Bioworld Technology, Inc. (St. Louis Park, MN, USA). Anti-green fluorescent protein (GFP) antibody (11814460001; 1:1,000) was obtained from Roche Diagnostics (Indianapolis, IN, USA). Recombinant human TRAIL was produced by PeprTech, Inc. (Rocky Hill, NJ, USA), and PP2, PP3 and U0126 were purchased from Sigma-Aldrich (St. Louis, MO, USA).

DNA constructs. pcDNA3.0-GFP-arrestin1/2 and pBS-U6- β -arrestin1/2 were provided by Dr. Gang Pei (Chinese Academy of Sciences, Shanghai, China). All expression vectors were sequenced and purified using the EndoFree Plasmid Preparation kit (Qiagen China Co., Ltd., Shanghai, China).

Cell culture and transfection. Hepatic carcinoma (HepG2) cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Invitrogen Dulbecco's modified Eagles's medium (DMEM; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% (v/v) fetal bovine serum (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) and 1% antibiotics (100 U/ml penicillin and 100 μ g/ml streptomycin; Hyclone) at 37°C and 5% CO₂ in a fully humidified incubator. Transient transfection was performed using the Fugene® HP Transfection Reagent (Roche) according to the manufacturer's instructions. The total quantity of DNA was normalized to empty control plasmids.

Co-immunoprecipitation and immunoblotting analysis. Cells were rinsed twice with ice-cold phosphate-buffered saline (PBS) and lysed on ice in a lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) containing 20 mM Tris (pH 7.5), 2 mM EDTA, 135 mM NaCl, 2 mM dithiothreitol, 25 mM β -glycerophosphate, 2 mM sodium pyrophosphate, 10% glycerol, 1 mM Na₃VO₄, 1% Triton X-100, 10 mM NaF, 10 μ g/ml leupeptin, 10 μ g/ml aprotinin, and 1 mM

phenylmethanesulfonyl fluoride supplemented with 0.01% complete protease inhibitor cocktail (Roche) for 30 min. Lysates were centrifuged at 12,500 x g for 15 min at 4°C. Equal quantities of proteins were immunoprecipitated overnight with β -arrestin2 monoclonal antibody at 4°C. The precleared Protein A/G PLUS-Agarose beads (20 μ l; Santa Cruz Biotechnology, Inc.) were co-incubated with immunocomplexes for an additional 2 h, then washed four times with the cold lysis buffer. The immunoprecipitates were electrophoresed on 12% SDS-PAGE (135 V; 2 h) and transferred onto nitrocellulose membranes (GE Healthcare Life Sciences). Immunoblotting was subsequently performed. The LI-COR Odyssey Infrared Imaging system and IRDye® 800 fluorephore-conjugated antibody (LI-COR Biosciences, Lincoln, NE, USA) were used to visualize the antibody-antigen complexes. Band intensity quantification was directly performed on the blot using LI-COR Odyssey Analysis software 1.2. Aliquots of whole cell lysates were subjected to immunoblotting analysis to confirm appropriate protein expression.

RNA interference. HepG2 cells were transfected with short hairpin (sh)RNA constructs against β -arrestin1 or β -arrestin2 (pBS-U6- β -arrestin1 or pBS-U6- β -arrestin2), or a negative control vector using Fugene® HP Transfection Reagent according to the manufacturer's instructions. Interference efficiency was confirmed by immunoblot analysis following a 72-h transfection using β -arrestin1 or β -arrestin2 antibodies.

Flow cytometry. Cell apoptosis was determined using the Annexin V/propidium iodide (PI) double staining assay (Kaiji Materials Co., Ltd., Nanjing, China). Briefly, following transfection with shRNA or a negative control vector, the cells were washed with PBS, harvested by trypsinization, precipitated by centrifugation (2,000 x g for 5 min), rinsed with PBS again, resuspended with 500 μ l binding buffer, and stained with Annexin V and PI. Apoptotic cells were detected directly using the Guava Easy Cyte™ system, and the data were analyzed using Guava TUNEL Software (Guava Technologies, Inc., Hayward, CA, USA).

Cell viability assay. Cell viability was determined using a Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology) according to the manufacturer's instructions. Briefly, HepG2 cells were seeded at a density of 1x10⁴ into 96-well plates 24 h before treatment. Cells were pretreated with PP2 (5 μ M), PP3 (5 μ M) or 0.1% dimethyl sulfoxide (DMSO) for 2 h, then exposed to 200 ng/ml TRAIL for 24 h, followed by incubation with 10 μ l CCK-8 working solution at 37°C for 2 h. The absorbance of each well at a wavelength of 450 nm was measured using a Synergy2 multi-mode microplate reader (Bio-Tek, Inc.). Three experiments were performed for each of the different treatments.

Immunofluorescence microscopy and 4',6-diamidino-2-phenylindole (DAPI) staining. HepG2 cells were preincubated with PP2 (5 μ M), PP3 (5 μ M) or 0.1% DMSO for 2 h, then stimulated with TRAIL; the cells were subsequently fixed with 4% paraformaldehyde (JRDun Biotechnology, Co., Ltd., Shanghai, China) and permeabilized with 0.2% Triton X-100. Following incubation with 1 μ g/ml DAPI for 5 min at room




Figure 1. β -arrestin2 mediated TRAIL-induced apoptosis. HepG2 cells were transiently transfected with pBS-U6- β -arrestin1 and 2 or control plasmid, pBS-U6. After a 72-h transfection, HepG2 cells were treated with 200 ng/ml TRAIL for the indicated times. (A and B) Expression levels of PARP, pro-caspase-3 and cleaved caspase-3 were detected by western blotting. (C) Apoptotic ratios were detected by flow cytometry. The lower left quartile represents live cells, the lower right quartile represents early apoptotic cells, the upper left quartile represents dead cells and the upper right quartile represents late apoptotic cells. Experiments were performed in triplicate and data are presented as means \pm standard deviation. * $P < 0.05$ vs. control. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; PARP, poly ADP ribose polymerase; RNAi, RNA interference; Arrb, β -arrestin.

temperature, the cells were washed with PBS again. The immunofluorescence images were captured using a fluorescence microscope (Leica TCS SP8; Leica Microsystems GmbH, Wetzlar, Germany). The number of cells exhibiting nuclear condensation and fragmentation were counted in randomly selected fields, and the ratio of these cells to the total number of cells was calculated.

Statistical analysis. Data are presented as the mean \pm standard deviation. One-way analysis of variance was used to determine significant differences between two groups. $P < 0.05$ was considered to indicate a statistically significant difference. Statistical calculations were performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA).

Results

β -arrestin2 inhibited TRAIL-induced apoptosis in HepG2 cells. A previous study demonstrated that β -arrestins prevented cell apoptosis via the ERK, p38 and Akt signaling pathways (4), which are involved in cancer progression (7,15). Furthermore, TRAIL has previously demonstrated marked anticancer effects in numerous tumor types, but not in normal cells (10). Conversely, previous studies reported that certain human cancers were resistant to TRAIL (11,12,16,17),

although the underlying molecular mechanisms were unclear. The present study hypothesized that β -arrestins are involved in TRAIL-resistance by combining with pro-survival signaling molecules and regulating their activity.

In the present study, the role of β -arrestins in the TRAIL-induced apoptosis of HepG2 cells was evaluated. HepG2 cells were transiently transfected with pBS-U6- β -arrestin1 and 2 or control plasmid. Following a 72-h transfection, HepG2 cells were treated with 200 ng/ml TRAIL for 6, 12 or 24 h, and cell lysates were analyzed by western blotting. Following TRAIL stimulation, cleaved PARP and cleaved caspase-3 expression levels were increased, whereas the protein expression level of pro caspase-3 was decreased, in a time-dependent manner. In addition, as compared with the control vector, the cleaving of PARP and caspase-3 was markedly enhanced, whereas the pro-caspase-3 expression level was significantly reduced, in pBS-U6- β -arrestin2 transfected cells. However, there was no significant difference identified between the level of apoptosis-associated proteins in the pBS-U6- β -arrestin1 and the control vector transfected cells (Fig. 1A and B). These results suggest that β -arrestin2, but not β -arrestin1, is involved in TRAIL-induced HepG2 cell apoptosis.

To further investigate the role of β -arrestins in modulating TRAIL-induced HepG2 cell apoptosis, the apoptotic ratio was




Figure 2. Overexpression of β -arrestin2 attenuated TRAIL-induced apoptosis. HepG2 cells were transiently transfected with pcDNA3.0 and GFP-Arrb2 plasmids for 48 h. Certain cells were stimulated with TRAIL for 24 h. (A) Cell lysates were prepared and subjected to immunoblotting with the indicated antibodies. (B) Apoptotic ratios were detected by flow cytometry. The lower left quartile represents live cells, the lower right quartile represents early apoptotic cells, the upper left quartile represents dead cells and the upper right quartile represents late apoptotic cells. (C) The overexpression efficiency of β -arrestin2 was detected by western blotting. (D) HepG2 cells were transiently transfected with pBS-U6- β -arrestin2 and control plasmid, pBS-U6 for 72 h. HepG2 cells were subsequently transiently transfected with pcDNA3.0 and GFP-Arrb2 plasmids for 48 h. Finally, certain cells were stimulated with TRAIL for 24 h. Cell lysates were prepared and subjected to immunoblotting with the indicated antibodies. Experiments were performed in triplicate and data are presented as means \pm standard deviation. * $P < 0.05$ vs. pcDNA3.0. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; PARP, poly ADP ribose polymerase; RNAi, RNA interference; Arrb, β -arrestin; GFP, green fluorescent protein.

detected using the AnnexinV/PI assay. The TRAIL-induced apoptotic ratio in β -arrestin2 RNA interference (RNAi) cells was 62.12% at 24 h, whereas the apoptotic ratio was 40.24% in the control plasmid transfected cells; however, no significant difference was observed between the apoptotic ratio of β -arrestin1 RNAi cells and control plasmid transfected cells (Fig. 1C).

To further clarify the role of β -arrestin2 in TRAIL-induced apoptosis, GFP-tagged β -arrestin2 (GFP-Arrb2) was overexpressed in HepG2 cells. Following a 48-h transfection, the cells were stimulated with TRAIL for 6, 12 or 24 h. As presented in Fig. 2A-C, caspase-3 and PARP cleavage, and the apoptotic ratio induced by TRAIL, were attenuated by overexpression of β -arrestin2 in HepG2 cells. To further demonstrate the role of

β -arrestin2 in TRAIL-induced apoptosis, β -arrestin2 shRNA was transiently transfected into HepG2 cells for 72 h, followed by transfection with GFP-Arrb2 or empty vectors for 48 h. As shown in Fig. 2D, the levels of cleaved caspase-3 and PARP in β -arrestin2 RNAi cells were reversed following overexpression with β -arrestin2 plasmid. These results demonstrate that β -arrestin2 exerts an anti-apoptotic role in TRAIL-induced HepG2 cell apoptosis.

β -arrestin2 mediated activation of the Src-ERK signaling pathway in response to TRAIL. It has been reported that TRAIL activates apoptosis signaling pathways, as well as survival signaling pathways, which are involved in the development of TRAIL resistance. The Src-ERK signaling pathway




Figure 3. β -arrestin2 mediated activation of the TRAIL-induced Src-ERK signaling pathway. (A) HepG2 cells were treated with TRAIL for 0.25, 0.5, 1, 2 or 4 h and the cell lysates were subjected to immunoblotting with the indicated antibodies. The band intensities were quantified by densitometry using LI-COR Odyssey Analysis software 1.2. * $P < 0.05$, ** $P < 0.01$ vs. the TRAIL⁻ group. HepG2 cells were transfected with (B) pBS-U6- β -arrestin2 or control plasmid for 72 h or (C) pcDNA3.0 and GFP-Arrb2 plasmids for 48 h. (B and C) Cells were stimulated with TRAIL for 1 or 2 h and the levels of p-, total Src and ERK were detected by western blotting. Equal protein loading was confirmed by GAPDH. (D) Cells were pretreated with 0.1% DMSO or 5 μ M PP2 or 5 μ M PP3 for 2 h, then treated with 200 ng/ml TRAIL. Cell lysates were prepared and subjected to western blotting using the indicated antibodies. (E) Cell viability was detected using a CCK-8 and experiments were independently repeated three times. * $P < 0.05$ vs. DMSO. (F) Cells were stained with DAPI and the nuclear morphology was observed by immunofluorescent microscopy (magnification, x200). (G) Cells were pretreated with 0.1% DMSO or 20 μ M U0126 for 2 h, then exposed to 200 ng/ml TRAIL for 24 h. Cell viability was detected by CCK-8 and experiments were independently repeated for three times. * $P < 0.05$ vs. DMSO. (H) Cells were stained with DAPI and the nuclear morphology was observed by immunofluorescent microscopy (magnification, x200). TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; p, phosphorylated; RNAi, RNA interference; Arrb, β -arrestin; GFP, green fluorescent protein; ERK, extracellular signal-regulated kinase; DMSO, dimethyl sulfoxide; CCK-8, Cell Counting Kit-8; DAPI, 4',6-diamidino-2-phenylindole.

was demonstrated to counteract TRAIL toxicity in tumor cells (18). Therefore, the activation of Src-ERK signaling upon TRAIL stimulation was investigated in the present study by western blotting. HepG2 cells were treated with 200 ng/ml TRAIL for 0.25, 0.5, 1, 2 or 4 h, and the levels of p-Src, p-ERK, total Src and ERK were detected by immunoblotting. As presented in Fig. 3A, Src and ERK were activated as a result of TRAIL stimulation. To investigate the potential role of β -arrestin2 in TRAIL-induced activation of Src and ERK, β -arrestin2 was knocked down in HepG2 cells via transfection of pBS-U6- β -arrestin2. Upon TRAIL stimulation, the downregulated expression of β -arrestin2 markedly reduced the phosphorylation of Src and ERK, although did not affect the total Src and ERK expression (Fig. 3B). To further evaluate

the effect of β -arrestin2 on the TRAIL-induced Src-ERK signaling pathway, GFP-Arrb2 plasmids and control vectors were transfected into HepG2 cells. Compared with the empty vector group, β -arrestin2 overexpression markedly facilitated the TRAIL-induced activation of Src and ERK (Fig. 3C). These results indicate that β -arrestin2 mediated activation of the Src-ERK signaling pathway upon TRAIL stimulation.

Src-ERK signaling pathway is involved in TRAIL-induced HepG2 apoptosis. It has been recognized that Src may mediate ERK activation and is an upstream kinase in various stimulus-induced signaling cascades (19,20). Therefore, PP2 was used to evaluate the effect of Src on the activation of ERK upon TRAIL stimulation. Blocking Src activity using PP2




Figure 4. β -arrestin2 formed a ternary complex with Src and DRs upon stimulation with TRAIL. HepG2 cells were treated with TRAIL for the indicated times, and the combinations of β -arrestin2 + Src, and β -arrestin2 + DRs were detected by co-immunoprecipitation analysis. The aliquot samples from the same lysates were used as inputs to determine the internal expression of β -arrestin2, DR4/DR5 and Src by immunoblotting. IgG served as a negative control. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; DR, death receptor; IgG, immunoglobulin G.

prevented TRAIL-induced phosphorylation of ERK (Fig. 3D). These results verified that, in HepG2 cells, Src serves as an upstream kinase in TRAIL-induced ERK pro-survival molecule activation. In order to further detect the role of the Src-ERK signaling pathway in TRAIL-induced HepG2 cell apoptosis, cell viability was examined with the CCK-8 and the nuclear morphology was detected by DAPI staining. HepG2 cells were pretreated with PP2 (5 μ M) or PP3 (5 μ M) for 2 h, then stimulated with TRAIL (200 ng/ml) for 24 h, and cell viability was detected. Fig. 3E demonstrates that PP2 inhibition of the activation of Src-ERK signaling reduced HepG2 cell viability markedly upon TRAIL stimulation. The DAPI-stained cells were detected by immunofluorescent microscopy. Furthermore, PP2 pretreated cells exhibited typical nuclear morphological changes of apoptotic cells, such as nuclear condensation and nuclear fragmentation, as compared with cells that were pretreated with PP3 (Fig. 3F).

U0126, an ERK inhibitor, was used to evaluate the effect of ERK in TRAIL-induced apoptosis. HepG2 cells were pretreated with 20 μ M U0126 or 0.1% DMSO for 2 h, and subsequently exposed to TRAIL (200 ng/ml) for 24 h. Cell viability was determined by the CCK-8 assay and cell nuclear morphology was observed by DAPI staining. Fig. 3G indicated that suppression of ERK activation also reduced cell survival, which was mediated by TRAIL. In Fig. 3H, U0126 pretreated cells exhibited marked nuclear condensation and nuclear fragmentation, as compared with cells that were pretreated with DMSO. These results indicate that Src-ERK signaling

pathway activation is involved in TRAIL-induced HepG2 cell apoptosis.

β -arrestin2, and Src and DR formed ternary complexes upon TRAIL stimulation in HepG2 cells. It has been reported that β -arrestins recruit signaling proteins, such as c-Src to ligand-bound G protein-coupled receptors (GPCRs) (21). However, the role of β -arrestins in DR signaling pathways remains unclear. To evaluate whether β -arrestin2 recruits Src to the TRAIL-associated DR, co-immunoprecipitation experiments were conducted in HepG2 cells. Cells were treated with TRAIL (200 ng/ml) for 0, 10 and 30 min, and β -arrestin2/Src/DR complexes were immunoprecipitated with the β -arrestin2 antibody. In addition, a portion of the cell lysate was analyzed prior to immunoprecipitation and served as a control (input). Co-immunoprecipitation analyses revealed that β -arrestin2 physically combined with Src, and TRAIL stimulation resulted in an increased quantity of the β -arrestin2-Src complex. Whether DRs were associated with the complex was subsequently investigated by detecting the presence of DRs in β -arrestin2 immunoprecipitates. Notably, the association of β -arrestin2 and DR4/5 following TRAIL stimulation was also observed (Fig. 4). These results indicate that DR/ β -arrestin2/Src ternary complexes are formed following TRAIL treatment. Employing other techniques, such as protein purification/co-elution experiments may validate this finding, and fluorescence resonance energy transfer (FRET)-based technology may aid with evaluating the mechanism of β -arrestin2-mediated Src-ERK signaling pathway activation. Further investigations are required to elucidate whether the mechanism is cell-type specific or universal, and establish the role of the ternary complex in TRAIL-induced HepG2 cell apoptosis.

Discussion

Recent studies have demonstrated that β -arrestins contribute to anti-apoptotic effects in apoptosis that is induced by a variety of stimuli (5,8,22). However, the role of β -arrestins in TRAIL-induced apoptosis remains unclear. In the present study, knockdown of β -arrestin2 in HepG2 cells increased cell apoptosis, and reduced activation of the Src-ERK signaling pathway upon TRAIL stimulation. Notably, TRAIL treatment enhanced the quantity of β -arrestin2/Src complexes and the association between β -arrestin2 and DR4/5 was observed only in the presence of TRAIL. These results indicate that β -arrestin2 acts as a negative regulator in TRAIL-induced HepG2 cell apoptosis via formation of ternary complexes and mediating activation of the Src-ERK signaling pathway.

TRAIL activates apoptosis signaling pathways and also survival signaling pathways (13), which may contribute to the development of TRAIL resistance (23). The Src-ERK signaling pathway is an important pro-survival signaling pathway and responds to different stimuli (20,24). In addition, recent studies revealed that β -arrestins serve as adaptors for scaffolding intracellular signaling networks to modulate downstream kinase activity (3). Therefore, the present study hypothesized that β -arrestins mediate Src recruitment, which could be involved in the effect of TRAIL on HepG2 cell apoptosis.

A cytoprotective role of β -arrestins was initially verified in HepG2 cells upon TRAIL stimulation. RNAi of β -arrestin2, but not β -arrestin1, potentiated TRAIL-induced apoptosis. Recent studies identified that β -arrestin1 exerted a significant role in the proliferation and anti-apoptotic activity of nicotine-induced human non-small cell lung cancer (25,26); the explanations were associated with differences in cell types and the specificity of the action of different arrestin subtypes. Recently, Kook *et al* (27) reported that β -arrestin1 was cleaved by caspases during apoptosis, which was not consistent with the present study. Kook *et al* (27) used mouse embryonic fibroblasts (MEFs) cells whereas the current study adopted HepG2 cells. β -arrestin has been demonstrated to have diverse roles via distinct mechanisms in various experimental models (22). In the present study, overexpression of β -arrestin2 using GFP-Arrb2 plasmids demonstrated that β -arrestin2 exerted anti-apoptotic role in HepG2 cells. Using β -arrestin2 RNAi and β -arrestin2 overexpression, the current results verified that β -arrestin2 has a significant role in TRAIL-induced HepG2 cell apoptosis. The contribution of β -arrestin2 to TRAIL-induced Src-ERK signaling activation was also demonstrated. Downregulating β -arrestin2 markedly attenuated the phosphorylation of Src and ERK upon TRAIL stimulation, and β -arrestin2 overexpression enhanced Src-ERK signaling pathway activation. To identify the role of Src activation in TRAIL-induced HepG2 cell apoptosis, PP2 was used to block Src phosphorylation, and the results demonstrated that suppression of Src activation following TRAIL treatment reduced the activation of ERK, and enhanced TRAIL-induced HepG2 cell apoptosis. In addition, U0126, an inhibitor of ERK, was used to block ERK phosphorylation, and a CCK-8 assay and DAPI staining revealed that inhibiting ERK activation prevented TRAIL-mediated cell survival. As a multifunctional scaffold, β -arrestins regulate various key signaling molecules through protein-protein interactions (28), thus, the association between β -arrestin2 and Src was examined further. The present study demonstrated that β -arrestin2 physically combined with Src, and the quantity of β -arrestin2 and Src complexes was enhanced upon TRAIL stimulation. It is proposed that β -arrestin2 regulated the activation of Src by increasing the number of β -arrestin2/Src complexes in response to TRAIL stimulation. It was reported that β -arrestins bind to Src family kinases and recruit them to activated GPCRs (29,30), which results in numerous physiological effects, including the generation of signal complexes where β -arrestins scaffold various proteins to potentiate distinct downstream signaling events (31). Using β -arrestin2 RNAi, β -arrestin2 was demonstrated to be important in regulating Src-ERK activation. Further investigation was performed to evaluate whether β -arrestin2 recruited Src to the TRAIL-associated DR. The present study demonstrated that TRAIL stimulation induced the formation of DR/ β -arrestin2/Src ternary complexes. However, the formation of ternary complexes could be validated more effectively with protein purification/co-elution experiments, or with FRET-based technology; therefore, further studies are required. The current data indicates that TRAIL may induce activation of the Src-ERK signaling pathway via formation of DR/ β -arrestin2/Src complexes. However, this requires further investigation. In addition, further studies are required to establish whether the ternary complex was necessary in β -arrestin2-mediated, TRAIL-induced HepG2 cell apoptosis.

In future studies, whether the formation of ternary complexes is cell-type specific or universal and the mechanism by which β -arrestin2 exerted its action on activation of the Src-ERK signaling pathway requires investigation.

In conclusion, the present study elucidated that β -arrestin2 protects HepG2 cells from TRAIL-induced apoptosis by facilitating the activation of Src-ERK pro-survival signaling. This may have been achieved by the recruitment of Src to DR by β -arrestin2 and the formation of DR/ β -arrestin2/Src ternary complexes in response to TRAIL stimulation. These findings provide novel insight into the mechanism by which β -arrestin2 protects cells against TRAIL-induced apoptosis.

Acknowledgements

The present study was supported by grants from the Natural Science Research Project of Anhui Colleges and Universities (grant no. KJ2016SD59), College Outstanding Young Talent Support Program Key Projects (grant no. gxyqZD2016173), the Natural Science Research Project of Anhui Provincial Education Department (grant no. KJ2013B311), the National Nature Science Foundation of China (grant no. 31301171) and the Anhui Province Key Laboratory of active biological macromolecules (grant no. 1306C083008). The authors would like to thank Dr. Zhimin Yin for assisting with the experiment.

References

- Shenoy SK and Lefkowitz RJ: β -Arrestin-mediated receptor trafficking and signal transduction. *Trends Pharmacol Sci* 32: 521-533, 2011.
- Violin JD and Lefkowitz RJ: Beta-arrestin-biased ligands at seven-transmembrane receptors. *Trends Pharmacol Sci* 28: 416-422, 2007.
- DeFea KA: Beta-arrestins as regulators of signal termination and transduction: How do they determine what to scaffold? *Cellular signalling* 23: 621-629, 2011.
- Yang X, Zhou G, Ren T, Li H, Zhang Y, Yin D, Qian H and Li Q: β -Arrestin prevents cell apoptosis through pro-apoptotic ERK1/2 and p38 MAPKs and anti-apoptotic Akt pathways. *Apoptosis* 17: 1019-1026, 2012.
- Zhang Z, Hao J, Zhao Z, Ben P, Fang F, Shi L, Gao Y, Liu J, Wen C, Luo L and Yin Z: Beta-Arrestins facilitate ubiquitin-dependent degradation of apoptosis signal-regulating kinase 1 (ASK1) and attenuate H_2O_2 -induced apoptosis. *Cell Signal* 21: 1195-1206, 2009.
- Wang Y, Tang Y, Teng L, Wu Y, Zhao X and Pei G: Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. *Nat Immunol* 7: 139-147, 2006.
- Hu S, Wang D, Wu J, Jin J, Wei W and Sun W: Involvement of β -arrestins in cancer progression. *Mol Biol Rep* 40: 1065-1071, 2013.
- Ahn S, Kim J, Hara MR, Ren XR and Lefkowitz RJ: β -Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. *J Biol Chem* 284: 8855-8865, 2009.
- Sun X, Zhang Y, Wang J, Wei L, Li H, Hanley G, Zhao M, Li Y and Yin D: Beta-arrestin 2 modulates resveratrol-induced apoptosis and regulation of Akt/GSK3 β pathways. *Biochim Biophys Acta* 1800: 912-918, 2010.
- Wu GS: TRAIL as a target in anti-cancer therapy. *Cancer Lett* 285: 1-5, 2009.
- Moon DO, Park SY, Choi YH, Ahn JS and Kim GY: Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: Involvement of ROS-dependent ER-stress. *Biochem Pharmacol* 82: 1641-1650, 2011.
- Guo SY, Liu SG, Liu L, Zhou XJ and Gu Y: RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF- κ B. *Oncol Rep* 27: 441-446, 2012.

13. Falschlehner C, Emmerich CH, Gerlach B and Walczak H: TRAIL signalling: Decisions between life and death. *Int J Biochem Cell Biol* 39: 1462-1475, 2007.
14. LeBlanc HN and Ashkenazi A: Apo2 L/TRAIL and its death and decoy receptors. *Cell Death Differ* 10: 66-75, 2003.
15. Álvarez CJ, Lodeiro M, Theodoropoulou M, Camiña JP, Casanueva FF and Pazos Y: Obestatin stimulates Akt signalling in gastric cancer cells through beta-arrestin-mediated epidermal growth factor receptor transactivation. *Endocr Relat Cancer* 16: 599-611, 2009.
16. Im SR and Jang YJ: Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells. *Biochem Biophys Res Commun* 424: 65-70, 2012.
17. Zhao J, Lu Y and Shen HM: Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. *Cancer Lett* 314: 8-23, 2012.
18. Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L, Luo L and Yin Z: HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with β -arrestin2. *Cell Signal* 26: 594-602, 2014.
19. Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S and Dent P: Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. *Cancer Biol Ther* 13: 793-803, 2012.
20. Park EJ, Chung HJ, Park HJ, Kim GD, Ahn YH and Lee SK: Suppression of Src/ERK and GSK-3/ β -catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells. *Food Chem Toxicol* 55: 424-433, 2013.
21. Pierce KL and Lefkowitz RJ: Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. *Nat Rev Neurosci* 2: 727-733, 2001.
22. Kook S, Gurevich VV and Gurevich EV: Arrestins in apoptosis. In: *Arrestins-Pharmacology and Therapeutic Potential*. Gurevich VV (Ed). Vol 219. 1st edition. Springer-Verlag, Berlin Heidelberg, pp309-pp339, 2014.
23. Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F and Mijatovic S: Resistance to TRAIL and how to surmount it. *Immunol Res* 52: 157-168, 2012.
24. Kim SR, Jung YR, Kim DH, An HJ, Kim MK, Kim ND and Chung HY: Caffeic acid regulates LPS-induced NF- κ B activation through NIK/IKK and c-Src/ERK signaling pathways in endothelial cells. *Arch Pharm Res* 37: 539-547, 2014.
25. Kim JI, Lakshmikanthan V, Frilot N and Daaka Y: Prostaglandin E2 promotes lung cancer cell migration via EP4- β Arrestin1-c-Src signalsome. *Mol Cancer Res* 8: 569-577, 2010.
26. Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, Lloyd M, Coppola D, Haura E and Chellappan SP: ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. *J Natl Cancer Inst* 103: 317-333, 2011.
27. Kook S, Zhan X, Cleghorn WM, Benovic JL, Gurevich VV and Gurevich EV: Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release and cell death. *Cell Death Differ* 21: 172-184, 2014.
28. Lodeiro M, Theodoropoulou M, Pardo M, Casanueva FF and Camiña JP: C-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and-dependent mechanisms. *PLoS One* 4: e4686, 2009.
29. Marchese A, Chen C, Kim YM and Benovic JL: The ins and outs of G protein-coupled receptor trafficking. *Trends Biochem Sci* 28: 369-376, 2003.
30. Laporte SA, Oakley RH, Holt JA, Barak LS and Caron MG: The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. *J Biol Chem* 275: 23120-23126, 2000.
31. Prossnitz ER: Novel roles for arrestins in the post-endocytic trafficking of G protein-coupled receptors. *Life Sci* 75: 893-899, 2004.